Lidosite Topical System Kit is a drug owned by Vyteris Inc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jun 29, 2021. Details of Lidosite Topical System Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6635045 | Electrodes and method for manufacturing electrodes for electrically assisted drug delivery |
Jun, 2021
(3 years ago) |
Expired
|
| US6629968 | Shelf storage stable iontophoresis reservoir-electrode and iontophoretic system incorporating the reservoir-electrode |
Jun, 2020
(4 years ago) |
Expired
|
| US6377847 | Iontophoretic drug delivery device and reservoir and method of making same |
Sep, 2013
(11 years ago) |
Expired
|
| US6385488 | Circuits for increasing the reliability of an iontophoretic system |
Sep, 2013
(11 years ago) |
Expired
|
| US5246418 | Iontophresis system having features for reducing skin irritation |
Sep, 2013
(11 years ago) |
Expired
|
| US5873850 | Locking and disfiguring mechanism for an iontophoretic system |
Sep, 2013
(11 years ago) |
Expired
|
| US6862473 | Iontophoretic drug delivery device and reservoir and method of making same |
Sep, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Lidosite Topical System Kit's patents.
Latest Legal Activities on Lidosite Topical System Kit's Patents
Given below is the list of recent legal activities going on the following patents of Lidosite Topical System Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 24 Mar, 2017 | US6862473 |
| Expire Patent Critical | 21 Nov, 2011 | US6635045 |
| Recordation of Patent Grant Mailed Critical | 01 Mar, 2005 | US6862473 |
| Patent Issue Date Used in PTA Calculation Critical | 01 Mar, 2005 | US6862473 |
| Issue Notification Mailed Critical | 09 Feb, 2005 | US6862473 |
| Receipt into Pubs | 01 Feb, 2005 | US6862473 |
| Dispatch to FDC | 31 Jan, 2005 | US6862473 |
| Application Is Considered Ready for Issue Critical | 31 Jan, 2005 | US6862473 |
| Issue Fee Payment Received Critical | 19 Jan, 2005 | US6862473 |
| Issue Fee Payment Verified Critical | 19 Jan, 2005 | US6862473 |
US patents provide insights into the exclusivity only within the United States, but Lidosite Topical System Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Lidosite Topical System Kit's family patents as well as insights into ongoing legal events on those patents.
Lidosite Topical System Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Lidosite Topical System Kit's generic launch date based on the expiry of its last outstanding patent is estimated to be Jun 29, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Lidosite Topical System Kit Generic API suppliers:
Epinephrine; Lidocaine Hydrochloride is the generic name for the brand Lidosite Topical System Kit. 13 different companies have already filed for the generic of Lidosite Topical System Kit, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Lidosite Topical System Kit's generic
About Lidosite Topical System Kit
Lidosite Topical System Kit is a drug owned by Vyteris Inc. Lidosite Topical System Kit uses Epinephrine; Lidocaine Hydrochloride as an active ingredient. Lidosite Topical System Kit was launched by Vyteris in 2004.
Approval Date:
Lidosite Topical System Kit was approved by FDA for market use on 06 May, 2004.
Active Ingredient:
Lidosite Topical System Kit uses Epinephrine; Lidocaine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Epinephrine; Lidocaine Hydrochloride ingredient
Dosage:
Lidosite Topical System Kit is available in patch form for iontophoresis, topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1.05MG/PATCH;100MG/PATCH | PATCH | Discontinued | IONTOPHORESIS, TOPICAL |